D
irect-acting antiviral agents (DAAs), combined in multidrug all-oral regimens, now represent standard-of-care therapy for patients with hepatitis C virus (HCV) infection. Treatment durations of currently approved regimens vary according to patient characteristics (notably HCV genotype and degree of liver fibrosis), but are typically between 8 and 24 weeks. (1, 2) Combining highly potent DAAs with different mechanisms of action may allow for shorter treatment durations that are effective across multiple genotypes. The short-duration, 6-week treatment regimen of sofosbuvir (SOF)/ledipasvir/vedroprevir demonstrated promising results in treatment-na€ ıve patients with HCV genotype (GT)1 infection (SVR [sustained virological response] of 95% (3) ), but less promising results when the same regimen was administered for 6 weeks in GT1-infected patients with F3/F4 fibrosis (SVR of 76% (4) ) or for 4 weeks in GT1-infected patients without cirrhosis (SVR of 20%-40% (5) ). In these studies, relapse was the most common form of virological failure. Successful retreatment of patients who relapsed following short-duration, all-oral therapy has been reported. (6) Among 34 patients who failed 4-6 weeks of treatment with ledipasvir/SOF with GS-9669 and/or GS-9451, retreatment with ledipasvir/SOF for 12 weeks achieved SVR rates of 91% (31 of 34); 1 patient relapsed and 2 withdrew from treatment. (6) SOF is a nonstructural (NS) 5B inhibitor that is approved in combination with ledipasvir for treatment of patients with HCV GT1 infection. (7) Elbasvir (EBR; MK-8742), an NS5A inhibitor, and grazoprevir (GZR; MK-5172), a potent NS3/4A inhibitor, have broad genotypic activity and have shown high efficacy across a wide spectrum of patients in phase II/ III clinical trials. (8) (9) (10) (11) (12) (13) (14) Given the differing mechanisms of action, broad in vitro genotypic activity, and high barrier to resistance of these three agents, we speculated that treatment regimens composed of these three potent DAAs administered for <12 weeks would be efficacious in patients with HCV GT1 or 3 infection. Given that GT3 has emerged as a particularly challenging genotype to treat with an all-oral regimen, this population was included to test the limits of efficacy of the three-drug regimen. Our objective was therefore to identify the minimum effective treatment duration across multiple genotypes that would subsequently support a pangenotypic development program. In addition, enrolling a DAA-exposed, resistance-associated variant (RAV)-enriched GT1a population offered a unique opportunity for assessing retreatment of previous DAA treatment failures. Herein, we report the results of the C-SWIFT study, which evaluated the safety and efficacy of the combination of EBR/GZR with SOF for 4, 6, or 8 weeks in previously untreated patients with or without cirrhosis with HCV GT1 or 3 infection. Because of the increased potential for relapse with short-duration therapy, we also report the outcomes of retreatment of GT1-infected patients who relapsed after initial short-duration therapy.
Patients and Methods

STUDY PATIENTS
The C-SWIFT study (ClinicalTrials.gov #NCT02133131; protocol PN074) enrolled treatmentna€ ıve adults aged 18 years with chronic HCV GT1 or 3 infection (HCV RNA >10,000 IU/mL) with or without compensated cirrhosis (determined by a liver biopsy, FibroScan, or FibroTest plus aspartate aminotransferase [AST]-to-platelet ratio index; see the Supporting Information). Patients with human immunodeficiency virus, decompensated liver disease, previous receipt of any anti-HCV treatment, alanine aminotransferase (ALT) >103 upper limit of normal (ULN), AST >103 ULN, creatinine clearance <50 mL/min, platelets <50 3 10 3 /lL, or serum albumin <3.0 g/dL were excluded.
STUDY DESIGN
This was an open-label, single-center, multiple-arm trial. All patients initially received the open-label, fixed-dose combination of EBR 50 mg/GZR 100 mg in combination with SOF 400 mg. Patients without cirrhosis with GT1 infection were randomized to 4 or 6 weeks of therapy and patients with cirrhosis with GT1 infection were randomized to 6 or 8 weeks of therapy, whereas patients without cirrhosis with HCV GT3 infection were randomized to 8 or 12 weeks of therapy and patients with cirrhosis with HCV GT3 infection received treatment for 12 weeks. Within the first three cohorts (GT1 without cirrhosis and with cirrhosis, and GT3 without cirrhosis), a separate randomization assigned patients into one of two groups defined by duration of therapy (4 or 6 weeks, 6 or 8 weeks, and 8 or 12 weeks) according to a computergenerated allocation schedule. All randomized patients were assigned a unique patient number, and treatment duration was provided within sealed disclosure envelopes that were opened at treatment week 4 for patients with GT1 infection and week 8 for those with GT3 infection. Within the fourth cohort (GT3 with cirrhosis), patients were assigned to the 12-week duration group (no randomization). Randomization of patients within the GT1 cohorts was stratified based on genotype subtype (1a vs. non-1a). At the time of enrollment, the investigators and patients were blinded to the treatment duration.
Patients with HCV GT1 infection who failed initial therapy were eligible for retreatment with EBR/ GZR1SOF and weight-based ribavirin (800-1,400 mg/day) for 12 weeks. To be eligible for retreatment, patients were required to have documented HCV GT1 infection before initial treatment and have failed initial treatment because of relapse. Patients with a serious AE during initial treatment, ALT/AST >103 ULN, decompensated liver disease, or hemoglobin <11 g/dL (female) or <12 g/dL (male) were excluded from retreatment. There was no specified minimum/maximum time between initial relapse and commencement of retreatment. Treatment of patients with HCV GT3 infection who failed initial therapy was continued outside the C-SWIFT protocol.
EFFICACY AND SAFETY ASSESSMENTS
The primary efficacy endpoint in both the initial treatment and retreatment phases was SVR12, defined as HCV RNA <15 IU/mL 12 weeks after the end of all study therapy. Virological failure was defined as breakthrough (confirmed HCV RNA 25 IU/mL after being <25 IU/mL previously while on treatment); nonresponse (detectable HCV RNA at end of treatment without achieving HCV RNA <25 IU/mL during treatment); rebound (confirmed >1 log 10 increase in HCV RNA from nadir while on treatment); or relapse (confirmed HCV RNA 25 IU/mL following end of all study therapy after having HCV RNA <25 IU/mL at end of treatment). Confirmation of HCV RNA status was achieved by testing of HCV viral load from a separate blood draw taken within 2 weeks of the initial test. Patients with confirmed virological breakthrough or rebound were discontinued from study medication. Safety was assessed through monitoring of adverse events (AEs), physical examination, vital signs, and standard laboratory evaluations. All patients were followed for 24 weeks after the end of all study therapy for efficacy outcomes and for 14 days after the end of all study therapy for safety analyses.
PROCEDURES
Plasma HCV RNA was measured using the Roche cobas AmpliPrep/cobas TaqMan HCV Test (version 2.0; Roche Molecular Diagnostics, Branchburg, NJ) on blood samples drawn from each patient at screening, days 1, 3, and 7, treatment weeks 2 and 4 (and 6, 8, and 12 if in 6-week, 8-week, or 12-week arm), and follow-up weeks 2, 4, 8, 12, and 24. The lower limit of quantification was 25 IU/mL and limit of detection was 15.1 IU/mL.
In treatment and retreatment phases, blood samples for viral resistance assays were collected from all patients at baseline (day 1) and at the time of failure in patients with confirmed virological failure. In the initial treatment study, population sequencing was used to detect the presence of variants known to confer resistance to NS3, NS5A, or NS5B inhibitors present at approximately 25% in the viral population. Complete NS3, NS5A, and NS5B genes were amplified using reverse-transcriptase polymerase chain reaction (RT-PCR), and resultant sequences were compared with reference wild-type sequences as described (further details are also available in the Supporting Information). (10) Postbaseline analyses were conducted by comparing the amino acid sequences at the time of virological failure to those at baseline (day 1, predose). In the retreatment study, baseline blood samples were assessed for the presence of RAVs using next-generation sequencing (NGS). In 1 patient, NGS data were not available, so population sequencing data were utilized. HCV RNA was reverse-transcribed and amplified using RT-PCR followed by library preparation, amplification using Nextera XT, and sequencing of the NS3, NS5A, and NS5B genes (llumina, MiSeq). Data quality control analysis and variant calling were performed using data with Q score >30. NGS data were analyzed at sensitivity thresholds of 1% and 15%.
STATISTICAL ANALYSIS
Approximately 30, 20, 15, or 10 patients were randomized to one of the seven treatment arms based on genotype and presence of cirrhosis. Assuming a protocol violation rate of 10%, the per-protocol population was to include 27, 18, 14, or 9 patients. The primary efficacy objective was to estimate rates of SVR12 for each treatment arm. A two-sided 95% confidence interval was constructed for each arm: No formal efficacy hypothesis testing was conducted.
According to the study protocol, the primary efficacy endpoint in the initial treatment study was assessed in the per-protocol population, which excluded patients with important deviations from the protocol that may substantially affect the primary efficacy analysis. A supportive analysis was performed based on the full analysis set, which included all allocated patients who received at least one dose of study medication. For reasons of transparency, in this report we have elected to describe the efficacy outcomes based on the full analysis set population, which are considered more representative of real-world clinical practice. The safety analysis was based on the All Subjects as Treated population, which included all patients who received at least one dose of study medication. For the purposes of this study, the full analysis set and All Subjects as Treated populations were identical. The resistanceanalysis population included all patients with baseline resistance data and a virological outcome of either SVR or relapse.
STUDY OVERSIGHT
The study was conducted in accord with principles of good clinical practice and the ethical guidelines of the Declaration of Helsinki and approved by the appropriate institutional review boards and regulatory agencies at each site. All patients provided written informed consent. Merck & Co., Inc. (the sponsor) contributed to the design and execution of the study and collection and analysis of the data. All co-authors had access to the study data, approved the final version of this report, and accept full responsibility for the veracity of the data. The protocol is available in the Supporting Information.
Results
PATIENTS
The study was initiated in June 2014 and the final patient completed treatment in November 2015. A total of 162 patients were screened; 19 failed to meet inclusion/exclusion criteria and 143 were randomized (GT1, n 5 102; GT3, n 5 41; Fig. 1 ). In total, 41 of 102 patients with GT1 infection and 12 of 41 with GT3 infection had cirrhosis. Forty-four percent (63 of 143) of patients had baseline HCV-RNA levels >2,000,000 IU/mL (Table 1) .
EFFICACY
Rates of SVR12 in patients without cirrhosis with GT1 infection were 32% (10 of 31) and 87% (26 of 30) in patients treated for 4 and 6 weeks, respectively (Fig. 2) . In GT1-infected patients with cirrhosis, SVR was 80% (16 of 20) in the 6-week treatment arm with four virological failures and 81% (17 of 21) in the 8-week treatment arm with two relapses (GT1 at baseline and GT1 at failure), 1 patient lost to follow-up, and 1 with a reinfection (GT1 at baseline and GT2 at failure). The rate of relapse in patients with cirrhosis with GT1 infection was 20% (4 of 20) with a 6-week duration and 10% (2 of 21) with an 8-week duration. Overall, 33 GT1-infected patients failed to attain SVR; 3 were discontinued for reasons unrelated to study medication and 30 relapsed, and no patient had on-treatment virological breakthrough. One patient with cirrhosis with HCV GT1 infection treated for 8 weeks was initially considered as a relapse and was subsequently found to have HCV GT2 infection at the time of relapse and was thus reclassified as a reinfection. The majority of relapse patients (20 of 30) were treated for 4 weeks: only 1 patient in the 8-week regimen had a true relapse. All patients with GT1 infection had undetectable HCV RNA after 2 weeks of therapy (Supporting Table S1 ).
Among GT3-infected patients without cirrhosis, SVR12 was 93% (14 of 15) after 8 weeks of treatment and 100% (14 of 14) after 12 weeks of treatment. SVR12 in HCV GT3-infected patients with cirrhosis was 83% (10 of 12). Of the 41 enrolled patients, 1 patient with GT3 infection discontinued for reasons unrelated to study drug (withdrawal because of work schedule) and 2 patients, 1 with cirrhosis and 1 without, who were randomized to the 8-week treatment arm relapsed. SVR12 was 95% (35 of 37) in patients with GT3 infection and baseline NS3 RAVs and 100% (3 of 3) in those with baseline NS5A RAVs (including A30K, L31M, and Y93H).
Subgroups typically included only small numbers of patients; however, suggestions of higher efficacy in patients with GT1 infection were noted in those with favorable characteristics, such as female sex, baseline viral load <800,000 IU/mL, IL28B-CC, and absence of baseline RAVs (Table 2 ). In the 6-week treatment arms, it is notable that all 8 relapsers were male and IL28B non-CC, and all except 1 had baseline viral load >800,000 IU/mL. In the 4-week treatment arm, SVR12 rates were low (30%-40%) regardless of the presence or absence of NS3 or NS5A RAVs at baseline. SVR12 rates increased in the 6-week treatment arms and were similar regardless of the presence or absence of NS3 RAVs (81% [26 of 32] and 89% [16 of 18] , respectively). They were also similar in patients without baseline receiving 6 weeks of therapy attained SVR12 (50% [2 of 4] ). Rates of SVR12 were generally high, regardless of presence or absence of NS3 or NS5A RAVs, in GT1-infected patients treated for 8 weeks. Overall, the higher SVR observed with 8 weeks of therapy may suggest that extending treatment duration beyond 6 weeks is able to overcome the negative influence of factors such as high baseline viral load, presence of baseline RAVs, and IL28B non-CC.
A more detailed analysis of the impact of RAVs on SVR12 is shown in Supporting Tables S2-S6. Supporting Table S2 shows that although the prevalence of baseline NS3 RAVs was 66% (65 of 98), there was no significant impact on the SVR12 rates in patients who received 4, 6, or 8 weeks of treatment, with an overall SVR12 rate of 76% (25 of 33) in patients without baseline NS3 RAVs compared with 69% (44 of 64) in those with baseline NS3 RAVs. In contrast, the presence of baseline NS5A RAVs did impact the SVR12 rates in patients treated for 6 or 8 weeks. The prevalence of baseline NS5A RAVs was 10% (7 of 69) in the 6-and 8-week treatment groups, with an overall SVR12 rate of 90% (55 of 61) in patients without baseline NS5A RAVs compared with 57% (4 of 7) in those with baseline NS5A RAVs. Efficacy was low in the 4-week treatment group, regardless of the presence or absence of baseline NS5A RAVs (33% vs. 30%, respectively).
There were 2 patients with GT3 infection who relapsed. Overall subgroup analyses of the GT3 population are based on small groups of patients and do not suggest any strong associations between patient characteristics and treatment outcomes. Abbreviation: NA, not available.
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RETREATMENT Twenty-five of the 30 patients (83%) with HCV GT1 infection who relapsed following the initial treatment were retreated with EBR/GZR1SOF and ribavirin for 12 weeks (Table 1) . Overall, 88% (n 5 22) were male, all were white, 88% (n 5 22) had GT1a infection, and 20% (n 5 5) had cirrhosis. Mean baseline viral load was 6.19 log 10 IU/mL. Seventeen retreated patients were previously treated for 4 weeks and 8 were previously treated for 6-8 weeks. Two patients were lost to follow-up (at day 3 and treatment week 4) and were therefore excluded from the efficacy analysis. The mean time from virological failure to enrollment in the retreatment study was 214 days (range, 182-260). All remaining 23 retreated patients achieved SVR12, including 18 patients without cirrhosis and 5 with, 15 previously treated for 4 weeks, and 8 previously treated for 6 or 8 weeks.
Analysis of the retreatment baseline resistance profile was performed using NGS methodology at 1% sensitivity threshold for 22 of 23 patients who had NGS data available; population sequencing data were used for the 1 patient who did not have NGS data. Overall, 14 patients (61%) had baseline NS5A RAVs (most commonly at positions 28, 30, and 31), 17 (74%) had baseline NS3 RAVs (most commonly Q80K), and none had baseline NS5B RAVs. Eleven patients (48%) had both NS5A and NS3 RAVs at retreatment baseline. All 23 retreated patients in the efficacy analysis set achieved SVR12. Notably, these include 11 of 11 patients with baseline NS5A and NS3 RAVs and 5 of 5 patients with cirrhosis FIG. 2. SVR12 (primary efficacy endpoint) for patients with HCV GT1 and 3 infection receiving EBR/GZR1SOF, and for patients with HCV GT1 infection undergoing retreatment with EBR/GZR1SOF and ribavirin (full analysis set). Abbreviations: 95% CI, 95% confidence interval; wks, weeks. *Genotyping of plasma samples taken at the time of virologic failure indicated that one of the patients with cirrhosis with HCV GT1 infection treated for 8 weeks had HCV GT2 infection present at time of failure. This patient was reclassified as a reinfection. Nonvirologic failures: -GT1 without cirrhosis 4 weeks: 1 patient lost to follow-up -GT1 cirrhosis 8 weeks: 1 patient lost to follow-up, 1 patient discontinued due to a serious adverse event -GT3 cirrhosis 12 weeks: 1 patient withdrew due to work schedule unrelated to adverse event.
( Fig. 3) . In addition, 3 of 3 patients with GT1a infection and linked baseline NS5A RAVs achieved SVR; 2 had linked RAVs known to confer >1,000-fold shift in potency to EBR in vitro (Q30K_Y93H and Q30H_Y93H). In these 2 patients, NGS sequencing indicated that both RAVs were present in >80% of patients, strongly suggesting that these were linked RAVs present within a single virus population.
A comparison of the prevalence of RAVs as assessed using NGS and population sequencing is shown in Supporting Table S7 . Use of population sequencing (sensitivity threshold 20%) revealed a lower proportion of patients with baseline RAVs compared with NGS (sensitivity threshold 1%).
SAFETY
Across all treatment arms, the most common AEs (>2% incidence overall) were fatigue (6%), headache (4%), nausea (4%), diarrhea (2%), and rash (2%). There was one serious AE of pneumonia, which led to discontinuation of therapy and was judged by the study investigator to be unrelated to study medication (Table 3) . There were no deaths, bilirubin elevations >53 baseline, or late elevations of ALT or AST >53 ULN.
During retreatment with EBR/GZR1SOF and ribavirin, the most common AEs were fatigue (16%), rash (12%), nausea (8%), and urinary tract infection (UTI; 8%). Eight patients reported a total of 13 drug-related AEs (fatigue, n 5 4; nausea, n 5 2; insomnia, UTI, papular rash, diarrhea, anemia, pruritic rash, and vomiting, n 5 1 each), all of which were mild to moderate in intensity and resolved with continued therapy. One patient reported a serious AE of emesis. This patient consumed an extra dose of EBR/GZR1SOF, which was followed by a single episode of emesis that lasted for 10 minutes and was not self-induced. One patient had a hemoglobin level <10 g/dL (this patient had a ribavirin dose reduction at treatment week 6 attributed to a hemoglobin level of 9.7 g/dL) and 1 patient discontinued ribavirin at treatment week 4 because of pruritus.
Discussion
This clinical study examined the treatment of patients infected with HCV GT1 or GT3 with or without cirrhosis with short durations of a novel regimen of EBR/GZR1SOF. Our data confirm that patients with and without cirrhosis with HCV GT1 *Full analysis set includes all allocated patients who received 1 dose of study medication. 
*Pneumonia on day 40 of treatment, which led to discontinuation of therapy. Serious AE was judged by the study investigator to be unrelated to study medication. † Late ALT/AST >53 ULN: elevations after treatment week 4 in ALT or AST >53 ULN. ‡ Most common AEs were defined as those in >2% of patients overall.
FIG. 3.
Prevalence of NS5A and NS3 RAVs and impact on SVR12 in patients undergoing retreatment. *Next-generation sequencing 1% sensitivity threshold (population sequencing data used for 1 patient who had a Y93N NS5A RAV infection can be cured with 6-8 weeks of treatment, and that an 8-to 12-week regimen of EBR/ GZR1SOF is safe and effective in patients with and without cirrhosis with HCV GT3 infection, commonly regarded as one of the most challenging patient populations to treat. Together, these data support the hypothesis that a DAA regimen of <12 weeks may be sufficient across multiple genotypes. Efficacy can be enhanced by including three mechanistically different agents, even in patients with cirrhosis. Furthermore, these data demonstrate that successful retreatment can be achieved with the same regimen by extending duration and adding ribavirin. An SVR rate of 100% was achieved with a 12-week regimen in a population highly enriched for RAVs and with the unfavorable demographics of HCV GT1a infection, cirrhosis, and high-impact RAVs. The present study incorporates several novel design elements. SVR12 rates of 95% were achieved with LED/GS-94511SOF for 6 weeks in the SYNERGY study. (3) Preclinical and phase 1 data indicate that EBR/ GZR1SOF is also a highly potent DAA combination and therefore support the evaluation of this triple DAA regimen in a short-duration study. (15) (16) (17) The patient populations examined also add to the novelty of this study: this study examined short-duration all-oral therapy in patients with HCV GT3 infection, and it also provides insight into the utility of short-duration therapy in patients with cirrhosis (both GT1-and 3-infected). Our results suggest that high efficacy rates can be achieved with 6 weeks of treatment in patients without cirrhosis with GT1 infection and that an 8-week treatment duration may be sufficient in GT1-infected patients with cirrhosis. The high efficacy rates achieved in patients with GT3 infection treated for 8-12 weeks provide proof of concept that an effective short-duration regimen might be achievable across even the hardest-totreat patient populations. Limitations of the present study include the single-center design and the small number of patients included in each treatment arm. These data require verifying in larger patient groups with a broader demographic profile.
The assessment of HCV RNA after 4 weeks of treatment provides insight into the limits of current therapeutic options. The high rates of relapse observed with 4 weeks of therapy in the present study and in morerecent studies (5) suggests that this treatment duration is too short to be of clinical value. In SYNERGY, SVR12 was also not improved when using a 4-week, four-drug regimen, with a higher barrier to resistance compared with the three-drug regimen. (3) Collectively, these data suggest that there may be a minimum time required to eliminate wild-type virus with the potency of current agents, and thus that treatment duration and not virological escape represents the principal limitation of the 4-week regimens. In the 6-week treatment arms, we noted a tendency toward higher SVR12 in patients with favorable characteristics, such as IL28B (also known as IFNL3) CC, low baseline viral load, and absence of baseline RAVs compared with patients with unfavorable characteristics. Within the 8-week treatment arm, favorable responses were noted across most patient subgroups. In the 6-and 8-week arms, SVR12 rates were numerically higher in female patients compared with male patients, similar to data reported in treatmentna€ ıve patients without cirrhosis with HCV GT1 infection receiving ledipasvir/sofosbuvir for 8 weeks. (18) These data, in combination with previous reports, therefore suggest that a 6-to 8-week treatment duration represents the lower bound of clinical utility, and that for selected patients, durations of 6-8 weeks may be sufficient to achieve SVR. However, the benefits of shortduration therapy (which include reduced cost and therefore increased accessibility and lower drug exposure/toxicity) must be balanced against the increased risk of relapse with these short-duration regimens. Therefore, for short-duration regimens to have clinical utility, effective management protocols must be established for patients who relapse. SVR12 in our retreatment study was 100% in a patient population that was notable because it was enriched for GT1a infection and NS5A RAVs at baseline. Concerns regarding short-duration therapy include whether ultrashort durations of 4 weeks provide sufficient time for complete eradication of the viral population. It is unknown whether the RAVs identified in patients at relapse were part of the existing quasi-species at baseline (at levels below those detected using population sequencing), or whether they were treatment emergent and selected for through drug pressure. Early data with another NS5A inhibitor, ledipasvir, suggest that RAVs emerging during treatment can persist through follow-up week 96 in up to 86% of treated patients, and that when present, these RAVs can impact future treatment attempts. (19, 20) Our data show that retreatment with a 12-week regimen incorporating four agents, each with a differing mechanism of action, provided an effective retreatment option. Most patients (80% [20 of 25] ) retreated in our study were without cirrhosis and had relapsed after an initial 4-week treatment regimen. However, most patients also had detectable RAVs at baseline, and our retreatment population included 5 patients with cirrhosis who all attained SVR. The proportion of patients with NS5A and NS3 RAVs at baseline in the retreatment study (61% and 74%) is driven primarily by the RAV profile within the population that relapsed following the initial 4-week treatment arm, which included a high proportion of patients with either baseline RAVs or treatment-emergent RAVs. It is unknown whether extending or reducing the interval between initial treatment and retreatment (214 days, or approximately 7 months, in our study) would affect treatment outcome. Collectively, our data suggest that many patients will attain SVR with 6-8 weeks of therapy and that high rates of SVR are achievable with 12 weeks of retreatment with a four-drug regimen in patients who fail. With increased scrutiny regarding the costs of new DAA regimens, it is tempting to speculate that short-duration regimens may represent a simple approach to increasing accessibility to treatment for more patients, with effective retreatment protocols available for the few patients who relapse.
The concept of shortening HCV therapy to 8 weeks while maintaining high rates of efficacy in HCV GT1-and 3-infected patients, even in those patients with cirrhosis, has been demonstrated by this study. Data from the present study support the use of shorter 8-week regimens that maintain high efficacy, even for patients infected with the most challenging HCV GT3 genotype. This study helps define the limits of treatment duration with current therapies and also shows the advantage of a three-drug regimen in overcoming the presence of baseline RAVs in HCV-infected patients. The regimen of EBR/GZR1SOF was generally safe and well tolerated. Retreatment of the patients who failed short-duration therapy was successfully achieved through extended treatment duration and the addition of ribavirin.
